Heparins and low-molecular-weight heparins
Heparins are injected anticoagulants. Low-molecular-weight heparins are fractions of heparin, and MeSH calls them effective antithrombotic agents. A US label for premixed heparin lists preventing and treating venous thrombosis and pulmonary embolism among its uses. This is the class page.
Also called Unfractionated Heparin · Low-molecular-weight heparins · LMWH
- Drug
- In this atlas
Overview
Technical summary
Class page. MeSH headings D006493 (Heparin) and D006495 (Heparin, Low-Molecular-Weight) are both broad matches: the first is one substance and the second is one half of this class. The scope note of the second says the fractions weigh usually between 4000 and 6000 kD. A US label for premixed heparin sodium says heparin inhibits the reactions that lead to blood clotting and fibrin clots, and lists prophylaxis and treatment of venous thrombosis and pulmonary embolism first among its uses. A US label for one low molecular weight heparin product describes it as a low molecular weight heparin and carries a boxed warning on epidural or spinal hematomas. Statements are scoped to each product. No trial result and no dose is recorded here.
Trials at a glance
The figures count the 13 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 13
- Phase 3 or 4
- 11
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 |
| Phase 3 | 2 | 0 | 1 | 3 |
| Phase 4 | 5 | 1 | 2 | 8 |
| No phase | 1 | 0 | 0 | 1 |
| All phases | 9 | 1 | 3 | 13 |
Conditions these trials study
- Heart attack (myocardial infarction)
- ST-elevation heart attack (STEMI)
- Chronic kidney disease (CKD)
- Deep vein thrombosis
- Pulmonary embolism
- Stroke
- Unstable angina
- Aortic stenosis
- Coronary artery disease
- Heart failure
Sponsors with the most trials
- Beijing Anzhen Hospital
- Christine Ribic
- Johns Hopkins University
- Laboratório Químico Farmacêutico Bergamo Ltda.
- Liverpool Heart and Chest Hospital NHS Foundation Trust
Drugs in this class
1 drug in this atlas is filed under Heparins and low-molecular-weight heparins, with the registry trials and FDA regulatory decisions this atlas holds for each. With Heparins and low-molecular-weight heparins itself, the class has 24 distinct trials and 35 distinct FDA decisions; a trial or decision that two of them share counts once there.
About this drug
- Level
- Class
- Mechanism
- Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots (US drug label for premixed heparin sodium).
Classification codes
-
D006493 -
D006495
Claims and evidence
No claims are published for this drug yet.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 13
Record details
- Record id
cardio:heparins-and-low-molecular-weight-heparins- Content hash
576148c6e940d60e8248663c4e1539c7bd78cbac3fd1b9f7cb4db18da8e884c9